Brentuximab vedotin for relapse or progression therapy after allogeneic hematopoietic stem cell transplantation in relapsed / refractory classic Hodgkin lymphoma

被引：0
|
作者：
Mikhailova, N. [1 ]
Popova, M. [1 ]
Kondakova, E. [1 ]
Ivanova, M. [1 ]
Borzenkova, E. [1 ]
Alaynskiy, A. [1 ]
Bondarenko, S. [1 ]
Afanasyev, B. [1 ]
Babenko, E. [1 ]
机构：
[1] First St Petersburg Pavlov State Med Univ, St Petersburg, Russia
来源：
BONE MARROW TRANSPLANTATION | 2016年 / 51卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P728
引用
收藏
页码：S503 / S503
页数：1
相关论文
共 50 条
  • [1] Brentuximab Vedotin Strategies for Relapsed Or Refractory Hodgkin's Lymphoma And Hematopoietic Stem Cell Transplantation
    Garzon-Velasquez, Katheryn
    Lizeth Acosta-Maldonado, Brenda
    Manuel Valero-Saldana, Luis
    Moreira-Ponce, Carolina
    Marcela Aguado-Vazquez, Tania
    Maylen Rivera-Fong, Liliana
    Rivas-Vera, Silvia
    BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 252 - 253
  • [2] ALLOGENEIC STEM CELL TRANSPLANTATION AND BRENTUXIMAB VEDOTIN IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A MULTICENTER EXPERIENCE
    Festuccia, M.
    Busca, A.
    Zallio, F.
    Sorasio, R.
    Brunello, L.
    Maffini, E.
    Dellacasa, C.
    Passera, R.
    Iovino, G.
    Aydin, S.
    Mordini, N.
    Pini, M.
    Boccadoro, M.
    Bruno, B.
    Giaccone, L.
    HAEMATOLOGICA, 2016, 101 : 320 - 320
  • [3] Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report
    Giannotti, Federica
    Ortiz, Carmen De Ramon
    Simonetta, Federico
    Morin, Sarah
    Bernardi, Chiara
    Masouridi-Levrat, Stavroula
    Chalandon, Yves
    Mamez, Anne-Claire
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [4] Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation
    Kaloyannidis, Panayotis
    Hertzberg, Mark
    Webb, Kate
    Zomas, Athanasios
    Schrover, Rudolf
    Hurst, Michael
    Jacob, Ian
    Nikoglou, Thalia
    Connors, Joseph M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (04) : 540 - 549
  • [5] Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation For Relapsed/Refractory Hodgkin Lymphoma In The Brentuximab Vedotin Era
    Anderlini, Paolo
    Saliba, Rima
    Ledesma, Celina
    Chancoco, Christina M.
    Alexander, Tamera R.
    Alousi, Amin M.
    Hosing, Chitra
    Khouri, Issa F.
    Nieto, Yago
    Popat, Uday R.
    Shpall, Elizabeth J.
    Fanale, Michelle A.
    Oki, Yasuhiro
    Romaguera, Jorge E.
    Neelapu, Sattva S.
    Younes, Anas
    Champlin, Richard E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S72 - S72
  • [6] Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
    Ishizawa, Kenichi
    Yanai, Tomoko
    ADVANCES IN THERAPY, 2019, 36 (10) : 2679 - 2696
  • [7] Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
    Kenichi Ishizawa
    Tomoko Yanai
    Advances in Therapy, 2019, 36 : 2679 - 2696
  • [8] Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin
    Howell, Matthew
    Gibb, Adam
    Radford, John
    Linton, Kim
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 179 (05) : 841 - 843
  • [9] Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
    Chen, Robert
    Palmer, Joycelynne M.
    Thomas, Sandra H.
    Tsai, Ni-Chun
    Farol, Len
    Nademanee, Auayporn
    Forman, Stephen J.
    Gopal, Ajay K.
    BLOOD, 2012, 119 (26) : 6379 - 6381
  • [10] Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era
    Hegerova, L.
    Cao, Q.
    Lazaryan, A.
    McClune, B. L.
    Weisdorf, D. J.
    Brunstein, C. G.
    Bachanova, V.
    BONE MARROW TRANSPLANTATION, 2017, 52 (05) : 697 - 703
12345